Zoryve launches in the U.S. for treatment of seborrheic dermatitis

Arcutis has officially launched sales for Zoryve topical foam 0.3% in the U.S. for the treatment of seborrheic dermatitis in individuals aged 9 years and older, according to a press release.
Approved by the FDA on Dec. 15, 2023, Zoryve (roflumilast, Arcutis) is a once-daily steroid-free foam and is the first drug approved in this indication with a new mechanism of action in more than 2 decades.
“Despite being a very common condition with significant negative impact on quality of life, seborrheic dermatitis has largely been overlooked by the pharmaceutical industry,” Todd Edwards,

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart